129 related articles for article (PubMed ID: 10917210)
1. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
Dummer R; Bergh J; Karlsson Y; Horowitz JA; Mulder NH; Huinink DTB ; Burg G; Hofbauer G; Osanto S
Cancer Gene Ther; 2000 Jul; 7(7):1069-76. PubMed ID: 10917210
[TBL] [Abstract][Full Text] [Related]
2. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma.
Sauter ER; Takemoto R; Litwin S; Herlyn M
Cancer Gene Ther; 2002 Oct; 9(10):807-12. PubMed ID: 12224020
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.
Shimada H; Matsubara H; Shiratori T; Shimizu T; Miyazaki S; Okazumi S; Nabeya Y; Shuto K; Hayashi H; Tanizawa T; Nakatani Y; Nakasa H; Kitada M; Ochiai T
Cancer Sci; 2006 Jun; 97(6):554-61. PubMed ID: 16734736
[TBL] [Abstract][Full Text] [Related]
4. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
[TBL] [Abstract][Full Text] [Related]
5. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
[TBL] [Abstract][Full Text] [Related]
6. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer.
Walther W; Siegel R; Kobelt D; Knösel T; Dietel M; Bembenek A; Aumann J; Schleef M; Baier R; Stein U; Schlag PM
Clin Cancer Res; 2008 Nov; 14(22):7545-53. PubMed ID: 19010873
[TBL] [Abstract][Full Text] [Related]
7. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
[TBL] [Abstract][Full Text] [Related]
8. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
Schuler M; Rochlitz C; Horowitz JA; Schlegel J; Perruchoud AP; Kommoss F; Bolliger CT; Kauczor HU; Dalquen P; Fritz MA; Swanson S; Herrmann R; Huber C
Hum Gene Ther; 1998 Sep; 9(14):2075-82. PubMed ID: 9759934
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
12. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
14. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
Cunningham CC; Chada S; Merritt JA; Tong A; Senzer N; Zhang Y; Mhashilkar A; Parker K; Vukelja S; Richards D; Hood J; Coffee K; Nemunaitis J
Mol Ther; 2005 Jan; 11(1):149-59. PubMed ID: 15585416
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
Tong AW; Nemunaitis J; Su D; Zhang Y; Cunningham C; Senzer N; Netto G; Rich D; Mhashilkar A; Parker K; Coffee K; Ramesh R; Ekmekcioglu S; Grimm EA; van Wart Hood J; Merritt J; Chada S
Mol Ther; 2005 Jan; 11(1):160-72. PubMed ID: 15585417
[TBL] [Abstract][Full Text] [Related]
16. Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis.
Gu J; Zhang L; Swisher SG; Liu J; Roth JA; Fang B
Oncogene; 2004 Feb; 23(6):1300-7. PubMed ID: 14676844
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
18. Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells.
Buttgereit P; Schakowski F; Märten A; Brand K; Renoth S; Ziske C; Schöttker B; Ebert O; Schroers R; Schmidt-Wolf IG
Cancer Gene Ther; 2001 Jun; 8(6):430-9. PubMed ID: 11498763
[TBL] [Abstract][Full Text] [Related]
19. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice.
Collinet P; Vereecque R; Sabban F; Vinatier D; Leblanc E; Narducci F; Querleu D; Quesnel B
J Obstet Gynaecol Res; 2006 Oct; 32(5):449-53. PubMed ID: 16984510
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Parker LP; Wolf JK; Price JE
Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
